




The relative strengths and weaknesses of Melinta Therapeutics INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Melinta Therapeutics INC NEW compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Melinta Therapeutics INC NEW is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 188%, being 32% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	70,374
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,345
Liabilities, Non-Current	0
Other Assets	321
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	7,623
Other Net Income	0
Other Revenues	0
Property and Equipment	43
Research and Development	83,728
Selling, General and Administrative Expense	21,562

Output Variable	Value in 1000 USD
Assets	70,738
Liabilities	12,968
Expenses	105,290
Revenues	0
Stockholders Equity	57,770
Net Income	-105,290
Comprehensive Net Income	-105,290
BaseVar	94,498
ECR before LimitedLiability	49%
Economic Capital Ratio	188%